Thus, this retrospective cohort study aimed to assess the efficacy of EGFR-TKIs alone or in combination with an antiangiogenic agent or chemotherapy as first-line therapy for patients with advanced NSCLC having concomitant EGFR and TP53 mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.